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Non-cell autonomous cues for 
enhanced functionality of human 
embryonic stem cell-derived 
cardiomyocytes via maturation of 
sarcolemmal and mitochondrial 
KATP channels
Wendy Keung1,2,*, Lihuan Ren1,2,*,  Sen Li1,2, Andy On-Tik Wong1,2, Anant Chopra3,4,  
Chi-Wing Kong1,2, Gordon F. Tomaselli5, Christopher S. Chen3,4 & Ronald A. Li1,6,7
Human embryonic stem cells (hESCs) is a potential unlimited ex vivo source of ventricular (V) 
cardiomyocytes (CMs), but hESC-VCMs and their engineered tissues display immature traits. In adult 
VCMs, sarcolemmal (sarc) and mitochondrial (mito) ATP-sensitive potassium (KATP) channels play crucial 
roles in excitability and cardioprotection. In this study, we aim to investigate the biological roles and 
use of sarcKATP and mitoKATP in hESC-VCM. We showed that SarcIK, ATP in single hESC-VCMs was dormant 
under baseline conditions, but became markedly activated by cyanide (CN) or the known opener P1075 
with a current density that was ~8-fold smaller than adult; These effects were reversible upon washout 
or the addition of GLI or HMR1098. Interestingly, sarcIK, ATP displayed a ~3-fold increase after treatment 
with hypoxia (5% O2). MitoIK, ATP was absent in hESC-VCMs. However, the thyroid hormone T3 up-
regulated mitoIK, ATP, conferring diazoxide protective effect on T3-treated hESC-VCMs. When assessed 
using a multi-cellular engineered 3D ventricular cardiac micro-tissue (hvCMT) system, T3 substantially 
enhanced the developed tension by 3-folds. Diazoxide also attenuated the decrease in contractility 
induced by simulated ischemia (1% O2). We conclude that hypoxia and T3 enhance the functionality of 
hESC-VCMs and their engineered tissues by selectively acting on sarc and mitoIK, ATP.
Cardiovascular disease is a leading cause of death worldwide1. Myocardial infarction typically injures a large 
enough number of cardiomyocytes (CMs), subsequently leading to heart failure whose last resort is organ trans-
plantation2. Human pluripotent stem cells, including embryonic stem cells (hESCs) and induced pluripotent stem 
cells (iPSC) are capable of self-renewal while maintaining their pluripotency to differentiate into all cell types 
including CMs. As such, hESC/iPSC provide a potentially unlimited ex vivo source of CMs for disease modelling, 
drug discovery, cardiotoxicity screening as well as cell replacement therapies. Despite such promises, it is now 
well accepted that hESC/iPSC-CMs and their engineered constructs are structurally and functionally immature 
with traits from weak contractile forces to higher susceptibility to apoptosis3–11 As such, there is a strong need to 
better understand the underlying basis of, and to derive effective strategies for driving maturation.
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ATP-sensitive potassium (KATP) channels, located on the sarcolemma and mitochondrial inner membranes 
of mature CMs, play an important role in cardioprotection during conditions such as ischemia by linking mem-
brane excitability to metabolism12–18. Under physiological conditions, KATP channels are closed due to endoge-
nous ATP inhibition19. When cytoplasmic ATP is depleted (e.g., during ischemia)20,21, sarcKATP opens to allow a 
repolarizing outward K+current, IK, ATP , thereby shortening the action potential (AP) and subsequently lowering 
Ca2+ influx to create a negative inotropic effect for metabolic conservation14,22–24. MitoKATP , originally demon-
strated through single channel recordings of ATP-sensitive K+currents in giant liver mitoplasts25. Was recently 
found to be composed of mitochondrial renal outer medullary potassium channel (ROMK) channel26. MitoKATP 
modulates ischemic preconditioning27,28, ischemic postconditioning29,30, and cytoprotection. Despite the crucial 
physiological role of KATP channels and the promises of hESC-CMs, neither sarc nor mitoIK, ATP in hESC-CMs has 
ever been studied. The present study aims to fill this gap, while seeking biological insights and developing effective 
means for driving maturation of hESC-CMs.
Result
Expression of sarcKATP channel subunit transcripts in hESC-VCMs. As a first step, microarray-based 
transcriptomic analysis was performed to examine the expression of the 4 genes that encode for sarcKATP chan-
nels (KCNJ8 for Kir6.1; KCNJ11 for Kir6.2; ABCC8 for SUR1; and ABCC9 for the two splice variants SUR2A and 
SUR2B) in hESC-VCMs (Fig. 1A). All of the four genes were detected in hESC-VCMs, but the expression levels of 
Kir6.1, SUR1 and SUR2 were about 10-folds lower than those of hF- and hA-VCMs while Kir6.2 were comparably 
lowly expressed. RT-PCR confirmed that all sarcKATP channel subunits were detectable in hESC-VCMs (data not 
shown).
Functional expression of sarcKATP channels in hESC-VCMs. Using these data as a guide, we func-
tionally confirmed for the first time the existence of sarcIK, ATP in hESC-VCMs. Electrophysiologically, sarcIK, ATP 
was dormant at baseline (1.05 ± 0.22 pA/pF at 0 mV, n = 8) but could be markedly activated by the metabolic 
inhibitor cyanide (CN; 2 mM) which decreases ATP production via inhibition of cytochrome C oxidase in the 
electron transport chain of the mitochondria (current density = 2.15 ± 0.35 pA/pF at 0 mV, n = 8; p < 0.05) 
(Fig. 1B–C). CN-induced sarcIK, ATP could be effectively and completely inhibited by the known sarcIK, ATP blocker 
glibenclamide (10 μ M) (1.27 ± 0.31 pA/pF at 0 mV, n = 8; Fig. 1B–C) or the specific inhibitor HMR1098 (100 μ M) 
(0.47 ± 0.11pA/pF at 0 mV, n = 9; Fig. 1D). Similarly, sarcIK, ATP in hESC-VCMs could be activated by the specific 
sarcIK, ATP opener P1075 (100 μ M) (3.11 ± 0.45 pA/pF at 0 mV, n = 7) and inhibited by HMR1098 (1.43 ± 0.19 pA/pF 
at 0 mV, n = 7) (Fig. 1E).
Functional effect of sarcKATP channel mediators on the AP phenotype of hESC-VCMs. As pre-
viously published, spontaneous AP firing is a developmental hallmark of immature hESC-VCMs5. Upon the 
addition of CN (2 mM), APD at 90% repolarization (APD90) significantly shortened (from 775.6 ± 129.7 ms 
to 385.3 ± 40.5 ms, n = 25, P < 0.05) (Fig. 2A,B), thereby hastening the spontaneous AP firing (0.88 ± 0.19 vs 
1.33 ± 0.32 Hz in control) (Fig. 2C). Other AP parameters such as the amplitude, upstroke velocity, decay velocity 
or maximal diastolic potential were not significantly altered (Table 1). Subsequently at steady-state, half of the 
CN-treated hESC-VCMs completely ceased firing (n = 12 of 25); the frequency of the remaining AP-firing cells 
reduced to 0.52 ± 0.16 Hz. For the CN-silenced cells, an AP could be elicited when given a single depolarizing 
stimulus, indicating the excitability of CN-treated cell remained intact (Fig. 2A). All CN effects were readily 
reversible upon washout or with the addition of glibenclamide (10 μ M) (Fig. 2A–C) or HMR1098 (Fig. 2D–F). As 
anticipated from the defined action of P1075 on sarcIK, ATP, similar effects on AP firing and properties which could 
be reversed by HMR1098 were observed (Fig. 2G–I).
Lack of effect of mitoKATP channel mediators on sarcIK, ATP and AP phenotype. In stark contrast 
to CN, GLI, P1075 and HMR1098, CN-mediated changes in sarcIK, ATP and AP were not altered by the mitoIK, ATP 
blocker 5HD (100 μ M) (Fig. 3A–D). Unlike CN, the mitoIK, ATP opener diazoxide (100 μ M) could not activate 
sarcIK, ATP (Fig. 3E) and had no effect on AP firing and parameters (Fig. 3F–G and Table 1).
Hypoxia drives sarcIK, ATP maturation in hESC-VCMs. Given the well-defined physiological role of sar-
cIK, ATP as a metabolic sensor in adult CMs20–24, we hypothesized that sarcIK, ATP in hESC-VCMs would respond 
to oxygen tension and change its expression accordingly21,31. To test this postulation, we subjected hESC-VCMs 
to a hypoxic condition (5% vs.20% O2) then compared their sarcIK, ATP and AP changes in response to sarcIK, ATP 
mediators to time-matched (normoxic) controls. Figure 4A,B shows that hypoxia time-dependently upregulated 
sarcIK, ATP with a ~3-fold increase in its current density at day 7. In contrast, neither electrical conditioning (at 
1 Hz for 14 days) that we previously showed to mature AP phenotype (by up-regulating IK1)5 nor thyroid hor-
mone treatment (10–100 nM triiodothyronine, T3, for 2 days) significantly altered sarcIK, ATP. As for the AP phe-
notype, CN significantly shortened APD90 and hastened AP firing of hypoxia-treated hESC-VCMs compared 
to un-treated controls, consistent with an up-regulated sarcIK, ATP (Fig. 4C). As anticipated, CN effect could be 
reversed by GLI.
MitoKATP was absent in untreated hESC-VCMs. MitoKATP signal was detected by confocal imaging of 
flavoprotein fluorescence. In the positive control isolated neonatal rat VCMs, both the non-specific opener DNP 
and the mitoKATP specific opener diazoxide significantly increased flavoprotein fluorescence reading by about 
1.7- and 1.1-fold, respectively when compared to controls (Fig. 5A), consistent with previously reported data28. 
By contrast, DNP increased the fluorescence of hESC-VCMs by only ~1.2 fold relative to controls. Diazoxide did 
not result in any significant changes (Fig. 5A), indicating that mitoKATP channels were not functionally present 
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Figure 1. Expression of sarcolemmal KATP channels in hESC-VCMs. (A) Top. Transcriptomic profile of the 
key molecular components of sarcolemmal KATP channels in hESC, hESC-VCMs, fetal VCMs (F-VCMs) and 
adult VCMs (A-VCMs) as revealed by microarray. Bottom.RT-PCR validated the expression of sarcKATP channel 
subunits in hESC-VCMs. (B) Top. Representative current tracings of sarcolemmal IK, ATP in hESC-VCMs at 0 mV 
under control conditions (blue line), with sodium cyanide (CN, 2 mM) alone (black line), and with CN and 
glibenclamide (GLI, 10 μ M, red line). Bottom. Summary of averaged current densities under the same conditions. 
Cells were stimulated to 0 mV for 1000 ms from a holding potential of − 80 mV preceded by a 100-ms prepulse 
to − 10 mV. N = 8; **P < 0.01 compared to control group; ##P < 0.01 compared to CN group. (C) Current-voltage 
relationships of IK, ATP under control conditions (blue line), with sodium cyanide (CN, 2 mM) alone (black line), 
and with CN and glibenclamide (GLI, 10 μ M, red line). The membrane potential was normally held at − 80 mV 
and the currents were evoked by a series of 1000 ms depolarizing and hyperpolarizing current steps (− 120 mV to 
+ 20 mV in 10 mV steps). N = 7. (D) Top. Representative current tracings of sarcolemmal IK, ATP in hESC-VCMs at 
0 mV under control conditions (blue line), with sodium cyanide (CN, 2 mM, black line) alone, and with CN and 
HMR-1098 (HMR, 100 μ M, red line). Bottom. Summary of averaged current densities under the same conditions. 
N = 9; **P < 0.01compared to control group; ##P < 0.01 compared to CN group. (E) Top. Representative current 
tracings of sarcolemmal IK, ATP in hESC-VCMs at 0 mV under control conditions (blue line), with P-1075 (P, 100 μ M,  
black line) alone, and with P and HMR-1098 (HMR, 100 μ M, red line). Bottom. Summary of averaged current 
densities under the same conditions. N = 7; **P < 0.01compared to control group; ##P < 0.01 compared to P group.
www.nature.com/scientificreports/
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in hESC-VCMs. These results were further confirmed by thallium uptake assay26. Neither diazoxide nor CN 
increased the thallium uptake rate of hESC-VCMs (Fig. 5B).
We next investigated the cardioprotective effect of mitoKATP channels during simulated ischemic (1% O2) by 
TUNEL assay. Neither DNP nor diazoxide could protect control hESC-VCMs from simulated ischemia-induced 
cell death. 5HD also did not lead to further cell death compared to their non-treated counterparts, suggesting 
that mitoKATP channel did not open to confer cardioprotection during ischemic/hypoxic insult (Fig. 5C and 
Supplemental Figure 1), consistent with the observation that functional mitoKATP is absent in hESC-VCMs.
Driven maturation of mitoKATP channels by triiodothyronine in hESC-VCMs. Since the thyroid 
hormone T3 is known to be involved in regulation of expression of cardiac genes32 and sensitivity of KATP chan-
nels to ATP33, we attempted to investigate the effect of T3 treatment on mitoKATP related actions in hESC-VCMs. 
When treated with T3 (100 nM) for 48 hrs, the cell circularity, a surrogate index of VCM maturity, of hESC-VCMs 
decreased (Fig. 5D). T3-treated hESC-VCMs also showed a progressive increase in calcium transient peak ampli-
tude and 90% decay velocity from day 2 to day 6 post treatment, consistent with a more mature calcium transient 
profile (Fig. 5D). This is further corroborated by an increase in expression of key calcium handling proteins 
including SERCA2a and phospholamban (data not shown). RNAseq analysis of T3-treated hESC-VCMs showed 
an increase in the expression of SUR2. which has been shown to be a subunit of mitoKATP34, while other subunits 
including Kir 6.1, Kir 6.2 and SUR1 was found to have decreased in expression (data not shown). Interestingly, T3 
treatment also increased the expression of ROMK (Fig. 5E), the major molecular constituent of mitoKATP26. Both 
diazoxide and CN significantly increased the thallium uptake rate in these T3-treated hESC-VCMs (Fig. 5B), 
demonstrating an increase in mito IK, ATP. Moreover, when treated with T3 for 48 hrs followed by a simulated 
ischemic insult for 8 hours, the % of TUNEL positive cells decreased in the presence of diazoxide (Fig. 5C). This 
Figure 2. Effects of the sarcolemmal IK, ATP blocker HMR1098 and opener P-1075 on the action potential 
properties of hESC-VCMs. (A) Representative action potential tracings of hESC-VCMs before and after 
sodium cyanide (CN, 2 mM) treatment with or without glibenclamide (GLI, 10 μ M). Early CN defined as CN 
treatment at the beginning (2–3 min). Late CN defined as steady-state after CN treatment. For this particular 
cell (12 cells), AP firing ceased in late CN application. Others (13 cells) showed significantly reduced firing 
frequencies. The arrow indicates an electrical stimulation (200 pA, 5 ms). (B,C) Bar plots summarizing the effects 
on AP parameters (B) APD90, (C) Firing Frequency N = 25; *P < 0.05, **P < 0.01compared to control; #P < 0.05, 
##P < 0.01 compared to late CN. (D) Representative action potential tracings of hESC-VCMs before and after 
sodium cyanide (CN, 2 mM) treatment with or without 100 μ M HMR-1098 (HMR). (E,F) Bar plots summarizing 
the effects on AP parameters. (C) APD90, (D) Firing Frequency. N = 18; *P < 0.05, **P < 0.01compared to 
control; #P < 0.05, ##P < 0.01 compared to late CN. (G) Representative action potential tracings of hESC-VCMs 
before and after P-1075 (100 μ M) treatment, with or without 100 μ M HMR-1098. AP firing ceased 5–10 minutes 
after P application (Late) in 4 of 14 cells. Others (10 cells) showed significantly reduced firing frequencies. 
(H,I) Bar plots summarizing the effects on AP parameters. G) APD90, (H) Firing Frequency N = 14; *P < 0.05, 
**P < 0.01compared to control group; #P < 0.05, ##P < 0.01 compared to late P-1075 group.
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effect could be inhibited by 5-HD. In contrast, the specific sarcKATP opener P1075 did not decrease the % of 
TUNEL positive cells after simulated ischemic insult. The specific sarcKATP inhibitor HMR1098 also showed no 
effect (Supplemental Figure 3). Interestingly, hypoxia and electrical field stimulation did not enhance mitoKATP 
channels in hESC-VCMs, indicating a cue-specific effect.
Effects of T3 on engineered human ventricular cardiac microtissues (hvCMT). To exploit the 
potential use of T3 for driven tissue maturation, we next examined the functional consequences of their treat-
ments on a multi-cellular 3D ventricular cardiac microtissue (hvCMT) system, where true dynamic tension 
developed by the tissue in real time, rather than shortening of single hESC-CMs or their clusters as an surrogate 
index for contractile forces35,36, can be measured. We reasoned that the improved calcium transient and cell sur-
vival induced by T3 would translate into stronger contractile forces at the tissue level, particularly after hypoxic 
insult. Figure 6A shows that hvCMT engineered from approximately 1000 hES2-VCMs each of ~0.3 mm in length 
which allowed continuous measurement of their dynamic twitch tension. To allow for thorough compaction of 
the tissues, hvCMTs were allowed to culture for 6 days with or without T3 treatment before dynamic twitch ten-
sions were measured. The developed twitch tension in T3 –treated, time-matched hvCMTs increased significantly 
(by 3-fold, P < 0.01, n = 6). However, the spontaneous twitch frequency was not altered by T3 (P > 0.05) (Fig. 6B). 
Consistent with an improved cell survival of T3-treated cells, T3-treated hvCMT displayed an attenuated decrease 
in developed tension after being subjected to simulated ischemia insult (1%O2) when treated with the mitoKATP 
opener diazoxide (Fig. 6C). The spontaneous twitch frequency was unaffected by T3 and diazoxide treatment 
(Fig. 6D).
Discussion
The roles of sarc and mito IK, ATP in excitability, cell viability and cardioprotection of adult CMs are well estab-
lished, but have not been tested in hESC-VCMs and their engineered tissues. In the present study, we tested the 
hypothesis that IK, ATP endows upon hESC-VCMs and their engineered tissues resilience to metabolic demand 
and ischemic insult. We found that although sarcKATP was expressed at a relatively low basal level in hESC-VCMs 
(~1/8 of adult), upon partial activation it was sufficient to cause APD shortening and therefore accelerated AP fir-
ing; when fully activated, sarcKATP of hESC-VCMs even silenced automaticity without compromising the intrin-
sic cellular excitability. These effects were even more prominent after hypoxia-driven augmentation of sarcKATP 
(by ~3-fold). By contrast, neither T3 treatment nor electrical conditioning (data not shown) affected sarcIK, ATP; 
this mirrored the upregulation of mito IK, ATP by T3 but not hypoxia, indicating cue-specific effects on sarc and 
mito IK, ATP. For hypoxia-treated hESC-VCMs, AP parameters were not changed under baseline condition when 
sarcoIK, ATP was dormant19. Sarcolemmal KATP has long been shown to be involved in cardioprotection during 
metabolic stress including ischemia/reperfusion21. While more recent studies point to mKATP as the key player in 
cardioprotection in ischemic37, sarcKATP has been shown to have an increased expression during preconditioning, 
with the increase expression of SUR2A. Thus, though the role of sarcolemmal KATP in cardioprotection is contro-
versial, our results which demonstrates that sarcolemmal KATP expression is increased in hESC-CMs after 2 days 
of hypoxia is in accord with previous studies in isolated cardiomyocytes. It has been shown that all subunits of 
KATP channels are expressed in low levels during fetal and prenatal phase, and continue to increase in expression 
after birth38. Chronic mild hypoxia has also been shown to increase SarcKATP31. Our observation that SarcKATP is 
increased in hypoxia may not serve as a pre-conditioning signal but rather in response to a developmental cue.
Unlike sarcKATP, mitoIK, ATP was not functionally expressed in hESC-VCMs. The protein of its molecular corre-
late ROMK was also absent. Given the defined role of mitoIK.ATP25,26, these findings may provide a potential expla-
nation, at least in part, for the poor graft survival after CM transplantation39,40 since the recipient milieu is often 
hostile and ischemic. Interestingly, upon T3 treatment, but not hypoxia, the expression of ROMK protein and 
mitoKATP were induced, along with an improved survival of hESC-VCMs after hypoxic insult. T3 treated engi-
neered ventricular tissues also maintained their contractile force after ischemic/hypoxic insult in the presence of 










Control (N = 88) 87.56 ± 1.45 5.73 ± 0.67 − 0.54 ± 0.03 − 68.62 ± 0.81
Early CN (N = 74) 81.99 ± 1.63 5.47 ± 0.83 − 0.68 ± 0.05 − 67.68 ± 0.94
Late CN (N = 74) 81.27 ± 1.88 5.82 ± 1.09 − 0.73 ± 0.05 − 67.76 ± 1.08
CN+ GLI (N = 25) 87.64 ± 3.22 5.22 ± 1.84 − 0.63 ± 0.08 − 71.66 ± 1.74
CN+ HMR (N = 18) 85.86 ± 3.66 5.84 ± 1.76 − 0.35 ± 0.04 − 67.37 ± 1.64
Early P (N = 14) 90.01 ± 3.32 10.80 ± 2.64 − 0.76 ± 0.09 − 71.99 ± 2.30
Late P (N = 14) 92.95 ± 3.38 13.14 ± 3.30 − 0.85 ± 0.13 − 74.27 ± 2.34
P+ HMR (N = 14) 91.74 ± 4.00 11.07 ± 2.91 − 0.70 ± 0.11 − 72.77 ± 2.25
CN+ 5HD (N = 13) 74.17 ± 3.63 7.57 ± 1.63 − 0.58 ± 0.13 − 59.78 ± 2.16
DIA (N = 18) 87.33 ± 3.17 3.59 ± 1.12 − 0.67 ± 0.06 − 70.73 ± 1.57
Table 1.  Summary of action potential parameters of hESC-VCMs under different treatment. CN: 
cyanide (2 mM); GLI: glibenclamide (10 μ M); HMR: HMR-1098 (100 μ M); P: P-1075 (100 μ M); 5HD: 
5-hydroxydecanoate (100 μ M); DIA: diazoxide (100 μ M). Early CN (or P) defined as the treatment at the 
beginning (2–3 min). Late CN (or P) defined as steady-state after the treatment.
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contractile forces of engineered ventricular tissue constructs were also enhanced after T3 treatment although the 
automaticity was not affected. Previous studies reported that T3 shortened action potential duration by decreas-
ing L-type calcium channel (Ica-L)41,42 and increasing transient outward potassium (Ito)43 and ultrarapid potas-
sium (IKur)42 current density. However, such was not observed in hESC-VCMs even one week after T3 (100 nM) 
treatment (Supplemental Figure 2). Indeed, RNA-seq data on hESC-VCMs reveals that the expression of L-type 
calcium channels was increased while the expression of Kir 2.1 was found to be unchanged after 7 -days T3 
treatment (data not shown). The increase in contractile forces observed in engineered tissues after T3 treatment 
Figure 3. Effects of the mitochondrial IK, ATP blocker 5-HD and opener Diazoxide on the action potential 
properties of hESC-VCMs. (A) Top. Representative current tracings of sarcolemmal IK, ATP in hESC-VCMs 
at 0 mV under control conditions (blue line), with sodium cyanide (CN, 2 mM, black line) alone, and with 
CN and 5-hydroxydecanoate (5HD, 100 μ M, red line). Bottom. Summary of averaged current densities 
under the same conditions. N = 6; **P < 0.01compared to control group. (B) Representative action potential 
tracings of hESC-VCMs before and after sodium cyanide (CN, 2 mM) treatment with or without 100 μ M 
5-hydroxydecanoate (5HD). C,D) Bar plots summarizing the effects on AP parameters. N = 13; *P < 0.05, 
**P < 0.01compared to control group. (E) Top. Representative current tracings of sarcolemmal IK, ATP in hESC-VCMs 
at 0 mV under control conditions (blue line), with diazoxide (DIA, 100 μ M, black line), or sodium cyanide 
(CN, red line). Bottom. Summary of averaged current densities under the same conditions. N = 7; **P < 0.01 
compared to control group. (F) Representative action potential tracings of hESC-VCMs before and after diazoxide 
(100 μ M) treatment, followed by sodium cyanide (2 mM) application. AP firing ceased 5–10 minutes after CN 
application (Late) in 9 of 18 cells. Others (9 cells) showed significantly reduced firing frequencies. (G,H) Bar plots 
summarizing the effects on AP parameters. N = 18; **P < 0.01 compared to control group.
www.nature.com/scientificreports/
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is likely due to the demonstrated improvement in calcium handling, which is a well established role of thyroid 
hormone and is independent of the cardioprotective effects conferred by mitoKATP . However, both effects are 
likely to be genomic in nature as long term treatment with T3 (in a matter of days) is required for these effects to 
be observed and that the effects persist after the removal of T3. The level of the thyroid hormone receptors TRα 
and TRβ are also observed to increase with T3 treatment (data not shown).
Collectively, our data suggest that sarcKATP is a prime candidate to target for electrophysiological stability and 
maturation, while mito IK, ATP engineering would improve the longevity of engraftment. We conclude that hypoxia 
and T3 enhance the functionality of hESC-VCMs and their engineered tissues by selectively acting on sarc and 
mitoIK, ATP. The results further implicate that multiple micro-environmental signaling cues uniquely interact to 
alter the expression and function of different gene products of hESC-VCMs. Therefore, a combinatorial approach 
will likely be needed for deriving more effective methods to drive maturation of hESC/iPSC-VCMs and their 
engineered tissues to a more adult-like state. A better understanding of the underlying key players and mecha-
nisms is crucial to accomplish this goal.
Figure 4. Driven maturation of IK, ATP in hESC-VCMs and the resultant functional consequences.  
(A) Representative sarcolemmal IK, ATP tracings, recorded in the absence (blue line) or presence of cyanide  
(CN, 2 mM, black line) with or without glibenclamide (GLI, 10 uM, red line) at 0 mV, of hESC-VCMs treated 
with hypoxia (5% O2 for 24–48 hrs, 7 and 14 days), electrical field stimulation (ES, 1 Hz for 14 days) or T3 
(10, 30, 100nM for 2 days). (B) Bar plots summarizing the IK, ATP densities at 0 mV under the corresponding 
conditions. **P < 0.01. N = 6, 12, 8, 5, 4, 2, 3, 2 for controls, hypoxia for 24–48 hrs, 7 days, ES, or 10, 30 or 
100 nM T3 for 2 days. **P < 0.01 compared to controls. (C) Representative action potential tracings and bar 
plots summarizing the effects on AP parameters of hESC-VCMs subjected to hypoxia (5% O2) for 7 days. 
The percentage of APD shown in the bar plots is the ratio of APD in CN treatment over APD in CN with GLI 
treatment. N = 4 and 7 for controls and hypoxia for 7 days. *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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Figure 5. Role and driven maturation of mitochondrial IK, ATP activity in hESC-VCMs. (A) Time course of 
changes in flavoprotein fluorescence in neonatal rat VCMs and hESC-VCMs exposed to DNP (100 μ M, blue), 
diazoxide (DIA, 100 μ M, red) and control (black) buffer as indicated. N = 4 for each. (B) Thallium assays in 
hESC-VCMs with or without T3 treatment (100 nM for 2 days). The representative tracing and summarized 
thallium uptake rate of hESC-VCMs or T3-treated hESC-VCMs exposed to control (black) buffer, diazoxide 
(DIA, 100 μ M, red) or cyanide (CN, 2 mM, blue). N = 79, 40 and 29 for control, DIA and CN in hESC-VCMs, 
26, 68 and 25 for control, DIA and CN in T3-treated hESC-VCMs. **P < 0.01. (C) TUNEL assay of normoxia 
and hypoxia (1% O2)-treated hESC-VCMs and 300 nM T3-treated hESC-VCMs, in the presence of diazoxide 
(100 μ M) with or without 5HD (1 mM) as indicated. N = 8. *P < 0.05. (D) Cell circularity and APD90 in hESC-VCMs 
after T3 treatment for 2 and 6 days. N = 16 and 26 for 2 days and 6 days respectively. *P < 0.05. (E) ROMK 
expression in hESC-VCMs after T3 treatment. Mitofusin-2 is shown as a mitochondrial marker.
www.nature.com/scientificreports/
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Methods
Human ESC culturing and directed cardiac differentiation. Undifferentiated hESC (hES2) were 
maintained in mTeSR™ 1 on matrigel (BD)-coated plates. Direct cardiac differentiation was initiated with a mod-
ified embryoid body formation protocol44. To initiate cardiac differentiation, hESCs were dissociated into single 
cells using Accutase (Invitrogen) and cultured in mTeSRTM1 medium with MatrigelTM (40 μ g/ml), BMP-4 (1 ng/ml, 
Invitrogen) and Rho kinase (ROCK) inhibitor (10 μ M; R&D) under hypoxic (5% O2) condition. Twenty-four 
hours later, the culture was washed and replaced in StemPro34 SFM (Invitrogen) with ascorbic acid (AA, 50 μ g/ml; 
Sigma), 2 mM GlutaMAX-1 (Invitrogen), BMP4 (10 ng/ml) and human recombinant activin-A (10 ng/ml; 
Invitrogen) for 3 days. On day 4, IWR-1, a small molecule Wnt inhibitor, (5 μ m/ml; Enzo Life Sciences) was 
added to inhibit the canonical Wnt signaling. On day 8, cells were transferred to normoxic environment and 
Figure 6. Role and driven maturation of mitochondrial IK, ATP activity in hvCMTs. (A) Developed tension 
of hvCMTs with or without T3 treatment for 6 days. Top. Representative tracing of tension changes during 
spontaneous contraction of hvCMTs. Bottom. Bar graph showing average developed tension in control and T3 
treated hvCMTs during spontaneous contraction. N = 6 for both control and T3. p < 0.05. (B) Spontaneous 
contraction frequency in control and T3 treated hvCMTs at day 6 after seeding. N = 6 for both control and 
T3.(C) Developed tension of hvCMTs with or without T3 treatment after simulated ischemic insult. Top. 
Representative tracing of tension changes during spontaneous contraction of hvCMTs after 8 hrs hypoxia 
(1%O2) and reoxygenation treatment. Bottom. Bar graph showing average developed tension in hvCMTs 
before and after hypoxia/reoxygenation treatment. N = 4 for all groups. p < 0.05. (D) Spontaneous contraction 
frequency in control and T3 treated hvCMTs at day 6 after seeding. N = 4 for all groups.
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maintained in StemPro34 SFM + AA medium. Around 20 days post cardiac differentiation, cardiac clusters were 
dissociated for 5 min by 0.05% trypsin in PBS without calcium and magnesium, followed by transferring to 
Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) with 5% fetal calf serum, 2 mML-glutamine, 1% pen-
icillin/streptomycin and 100 μ M non-essential amino acids solution (Invitrogen). The cultures were maintained 
under an atmosphere of water saturated 5% CO2/95% air at 37 °C. Twenty-four hours later, cells were transduced 
with the lentiviral construct LV-MLC2v-tdTomato-T2A-Zeo that we previously published and described7. Three 
days after transduction, zeocin (300 μ g/ml) was used to select for hESC-VCMs. The selected VCMs were used for 
downstream experiments at 30 days post-differentiation.
Isolation of human fetal and adult ventricular CMs. Human fetal and adult left ventricular CMs 
were isolated in accordance to regulations, guidelines and protocols approved by the UC Davis IUPAC and IRB 
Protocol (#200614787-1 and #200614594-1) with written informed consent given for the use of the human tissue.
All fetal (18–20 weeks) and adult (50–70 years) hearts were digested using the Langendorff system with a 
recirculatory system that circulated the 37 °C collagenase solution until cells started to dissociate into the enzyme 
solution. The fetal hearts typically took about 30min and the adult hearts took over 3 hours to digest. The colla-
genase solution contained 200 U/ml collagenase II (Worthington Biochemical Corp), 4 mg protease (Sigma) with 
1% BSA. After enzyme treatment, the hearts were chopped manually to release the cells into high K+ solution. 
The fetal cells were plated for 1 hour in M199 with 5 mM carnitine, 5 mM creatine, 5 mM taurine, 10% FBS and 1% 
penicillin/streptomycin to remove fibroblasts. The medium was then collected to retrieve the CMs in suspension. 
The adult cells were not plated but allowed to settle by gravity for 15 min. The denser CMs at the bottom of the 
conical tubes were collected.
Isolation of rat neonatal ventricular cardiomyocytes. The use of animals and all experimental pro-
tocols in this study were approved by the Committee on the Use of Live Animals in Teaching and Research of 
the University of Hong Kong. All animal experiments were performed in accordance with approved guidelines. 
Hearts from 2-day-old neonatal rats were isolated and rinsed in ice-cold phosphate-buffered saline (PBS) solu-
tion. After removal of the atria, the ventricles were minced with scissors and washed with ice-cold PBS washed 
three times in ice-cold PBS and digested with PBS containing DNase (0.025% w/v), collagenase (0.1%), and 
trypsin (0.05%) on a rotary shaker at 37 °C for 60 min. The digested cells were pelleted by centrifugation at 300 g 
and was resuspended in DMEM medium containing 5% fetal bovine serum, 10% horse serum, 50 μ g/ml gen-
tamicin) for differential plating. After serial plating, the resulting pellet was resuspended in plating media. The 
cells were plated at a density of 1.8–2.0 × 106 cells/plate.
Transcriptomic profiling. Microarray experiments were performed in hESC, hESC-VCMs, human 
fetal VCMs (hFVCMs) and human adult VCMs (hAVCMs). Cell samples were suspended and lysed in Trizol 
(Invitrogen). After adding 1:4 volume chloroform, aqueous and organic phases were separated using heavy PLG 
tubes (Eppendorf). Sentrix WG-6 beadchips (Illumina, San Diego, CA) were used to profile mRNA expression. 
Microarray data were analyzed using the BeadStudio for transcriptomic (Illumina) software packages. Expression 
was normalized using background subtraction and cubic spline (BeadStudio) or composite LOESS normalization 
(WebArrayDB).
Reverse transcription polymerase chain reaction (RT-PCR). RNA of hESC-VCMs was extracted by 
RNeasyPlus Mini Kit and cDNA was synthesized by QuantiTect Reverse Transcription Kit according to product 
protocol. AccuPrimeTMPfxSuperMix (Invitrogen) was used to perform PCR reactions by using the following 
primers: Kir6.1 (forward: CTGGCTGCTCTTCGCTATC and reverse: AGAATCAAAACCGTGATGGC), Kir6.2 
(forward: TGTCCCGCAAGGGCATCATCCCCG and reverse: TAGTCACTTGGACCTCAATGGAG), SUR1 
(forward: CGATGCCATCATCACAGAAG and reverse: CTGAGCAGCTTCTCTGGCTT), SUR2A (forward: 
ATATGGTCAAATCTCTACCTGGAGG and reverse: GTTGGTCATCACCAAAGTGGAAAAG) and SUR2B 
(forward: ATATGGTCAAATCTCTACCTGGAGG and reverse: CATGTCTGCGCGAACAAAAGAAGC).
Electrophysiology. The KATP channel currents and action potentials were recorded by whole-cell patch-clamp 
studies in hESC-VCMs at 37 °C using the EPC10 amplifier and Pulse/PulseFit software (HEKA, Germany) as pre-
viously described12. Patch electrodes (3.0–5.0 MΩ) were filled with the internal pipette solution containing 120 mM 
potassium glutamate, 25 mMKCl, 1 mM ATP (magnesium salt), 10 mM EGTA, 0.5 mM MgCl2 and 10 mM HEPES 
(pH 7.2). The external bath solution contained 140 mMNaCl, 5 mMKCl, 1 mM MgCl2, 1 mM CaCl2 and 10 mM 
HEPES (pH 7.4). Glibenclamide (Sigma-Aldrich), diazoxide (Sigma-Aldrich), 2, 4-dinitrophenol (Sigma-Aldrich) 
and P1075 (Santa Cruz Biotechnology) were dissolved in DMSO before they were added to experimental solutions. 
Sodium cyanide (Sigma-Aldrich), 5-hydroxydecanoic acid (Sigma-Aldrich) and HMR 1098 (Axon Medchem BV) 
were dissolved directly in external bath solution.
Confocal Imaging of flavoprotein fluorescence. The auto-fluorescence of mitochondrial flavoprotein 
protein was measured by Zeiss LSM700 confocal microscope with a 63x oil objective. Excitation wavelength of the 
solid state laser was set at 488 nm and emission was collected after 515 nm. Images were taken every 10 seconds.
Thallium Uptake Assay. Prior to the assay, cells were loaded with a fluorescent indicator, Fluozin-2 AM 
(5 μ M) (Invitrogen). The dye is sensitive to thallium, which is used to substitute for potassium. Dye was loaded 
in its acetoxymethyl ester (AM) form mixed with 0.2% (w/v) Pluronic F-127 prior to addition to the incubating 
medium. Cells were incubated with Fluozin-2 AM at 37 °C for 20 min, followed by two PBS washes to remove 
membrane bound dye. Just prior to the TI+ assay, cells were treated with 150 μ M digitonin for 30 seconds to 
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permeabilize the plasma membrane, as evidenced by rapid loss of the cytosolic component of dye, leaving only 
the mitochondrial compartment loaded with the indicator.
Images were collected by exciting at 488 nm and fluorescence was recorded by using Zeiss LSM700 confocal 
microscope. Bath TI+ was rapidly switched from 0 to 2 mM TI+ at 70 seconds. The chloride-free, 0 mM TI+ assay 
bath solution contained (in mM): 195 mannitol, 10 HEPES, 2 MgSO4, 2 Na2HPO4, 2 succinate, 0.6 CaOH and1 
EGTA (pH 7.2) and the 2 mM TI+ solution was identical except 2 mM TISO4 was added. Images were collected 
every 1.56 seconds, and the fluorescence intensities of the dyes were determined offline by ImageJ (NIH, USA). 
F/F0 was calculated for each timepoint (F0 was the basal fluorescence in the 0 Tl+ condition).
TUNEL assay on hypoxia. The hESC-VCMs or rat neonatal ventricular cardiomyocytes were seeded onto 
96-well plates for 24 hours to allow cell attachment. Cells were given T3 (100 nM) treatment for 2 days after which 
either vehicle or diazoxide (1 uM) were added before they were transferred to a hypoxic chamber maintained at a 
1% O2/5% CO2/95% N2 environment for 8 hours to simulate ischemia. The percentage of cell death was detected 
by TUNEL assay with the In Situ Cell Death Detection kit (Roche Biosciences, U.S.A). Briefly, the plates were 
washed with PBS and fixed in paraformaldehyde solution (4% in PBS) for 15 min at room temperature. The cells 
were permeabilized in a solution containing 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice, followed 
by incubation in freshly prepared TUNEL reaction mixture for 60 min at 37 °C in the dark. The plates were washed 
with PBS and counterstained with the DAPI for identification of nuclei. Samples were then imaged with Nikon 
Eclipse TiS microscope (Nikon Instrument Inc, Melville, NY, USA) and analyzed with Image J (NIH, USA).
Immunostaining. For staining of hESC-VCMs. adherent cells were fixed for 15 min at room temperature 
with 4% paraformaldehyde in phosphate-buffered saline (PBS). After washing with PBS, cells were permeabilized 
in PBS containing 1% Triton X-100 and subsequently blocked in 3% bovine serum albumin. Mitofusin-2 and 
ROMK1 (KCNJ1) antibodies were purchased from Abcam (Cambridge, MA, USA). Primary antibodies were 
diluted in PBS with 1% BSA at 1:200 and incubated at RT for 2 hours. Alexa Fluor (AF) 488-conjugated goat 
anti-rabbit IgG or AF555 anti-mouse IgG (Invitrogen) were used as secondary antibodies and stained for 1 hour 
at RT. Coverslips were mounted onto glass slides in Prolong Gold mounting medium with DAPI (Invitrogen) and 
samples were imaged on LSM Carl Zeiss 510 Meta (Carl Zeiss, Jena, Germany). Images were then analyzed and 
circularity index for each cell given by Image J (NIH, USA).
Quantification of contractile force in human ventricular cardiac microtissues (hvCMT). Human 
ventricular cardiac microtissues were prepared as previously described45. In brief, Polydimethylsiloxane (PDMS, 
Sylgard 184, Dow-Corning) microfabricated tissue gauges (μ TUG) substrates were molded from the SU-8 mas-
ters, with embedded fluorescent microbeads (Fluoresbrite 17147; Polysciences, Inc.) on the cantilever ends. 
Human ESC-VCMs were dissociated after trypsin digestion at 14–20 days post differentiation. The unpurified 
dissociated cells were used to produce microtissues and is composed of > 80% cTnT as determined by FACS 
analysis. A suspension of ~106 cells within the reconstitution mixture, consisting of 1.5 mg/mL liquid neutralized 
collagen I (BD Biosciences) and 0.5 mg/mL fibrinogen (Sigma-Aldrich), was added to the substrate and the entire 
assembly was centrifuged to drive the cells into the micropatterned wells, where hESC-VCMs self-assembled into 
microtissues within 24 hr. For quantifying microtissue forces, brightfield and fluorescence images were taken 
at 100 Hz with a fast CCD camera (Allied Vision), and an A-Plan 10x objective on a Nikon Eclipse Ti (Nikon 
Instruments, Inc.) equipped with a live cell incubator. Only tissues that were uniformly anchored to the tips of the 
cantilevers were included in the analysis. The displacement of fluorescent microbeads at the top of the cantilevers 
was then tracked with using the SpotTracker plug-in in ImageJ (National Institutes of Health). Microtissues were 
treated with the thyroid hormone triiodothyronine (T3, 100 nM) at the time of seeding for 6 consecutive days. 
Measurements were made on day 6 of T3 treatment. Microtissues were then transferred to a hypoxic chamber 
maintained at a 1% O2/5% CO2/95% N2 environment for 8 hours to simulate ischemia. They were then placed 
back to a normoxic environment for 8 hours after which force measurements on the same tissues were made 
again.
Data analysis. Data are presented as mean ± standard error of the mean (SEM) and number of cells is shown 
as N. Statistical comparison were evaluated by paired t-test for electrophysiological studies, unpaired t-test for all 
other assays. The accepted level of significance for the tests was P < 0.05.
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